Selected research
Industry Research
Mesalazine API Industry Research Report 2026
Market perspective
The global Mesalazine API market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Mesalazine API is forecast to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Mesalazine API is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Mesalazine API is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Mesalazine API include , among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Mesalazine API market in revenue (US$ million) and, where applicable, sales volume (t), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of types and applications, harmonizes vendor attribution, and presents comparable time series by company, type, application, and region/country, including indicative price bands (US$/t) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for manufacturers, new entrants, channel partners, and investors; the report also reviews technology shifts and notable product introductions relevant to Mesalazine API.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mesalazine API Market by Company
YC Biotech (Jiangsu)
Lianyungang Fengheng Biopharm
Hangzhou Brother
Syntese A/S
PharmaZell
Lasa Loboratory
Ishita Active Pharma Ingredients
Ipca Laboratories
Erregierre SpA
Divis Laboratories
CTX Lifescience
Corden Pharma Bergamo
Chemi SpA
Cambrex Corporation
Mesalazine API Segment by Type
Purity ≥ 99%
Purity ≥ 98%
Purity ≥ 97%
Mesalazine API Segment by Application
Suppository
Tablets
Granule
Capsules
Enema
Others
Mesalazine API Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalazine API market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalazine API and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalazine API.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mesalazine API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mesalazine API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mesalazine API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Purity ≥ 99%
- Purity ≥ 98%
- Purity ≥ 97%
Applications
- Suppository
- Tablets
- Granule
- Capsules
- Enema
- Others
Companies covered
- YC Biotech (Jiangsu)
- Lianyungang Fengheng Biopharm
- Hangzhou Brother
- Syntese A/S
- PharmaZell
- Lasa Loboratory
- Ishita Active Pharma Ingredients
- Ipca Laboratories
- Erregierre SpA
- Divis Laboratories
- CTX Lifescience
- Corden Pharma Bergamo
- Chemi SpA
- Cambrex Corporation
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Mesalazine API by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.2.2 Purity ≥ 99%
- 2.2.3 Purity ≥ 98%
- 2.2.4 Purity ≥ 97%
- 2.3 Mesalazine API by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Suppository
- 2.3.3 Tablets
- 2.3.4 Granule
- 2.3.5 Capsules
- 2.3.6 Enema
- 2.3.7 Others
- 2.4 Global Market Growth Prospects
- 2.4.1 Global Mesalazine API Production Value Estimates and Forecasts (2021-2032)
- 2.4.2 Global Mesalazine API Production Capacity Estimates and Forecasts (2021-2032)
- 2.4.3 Global Mesalazine API Production Estimates and Forecasts (2021-2032)
- 2.4.4 Global Mesalazine API Market Average Price (2021-2032)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mesalazine API Production by Manufacturers (2021-2026)
- 3.2 Global Mesalazine API Production Value by Manufacturers (2021-2026)
- 3.3 Global Mesalazine API Average Price by Manufacturers (2021-2026)
- 3.4 Global Mesalazine API Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Mesalazine API Key Manufacturers, Manufacturing Sites & Headquarters
- 3.6 Global Mesalazine API Manufacturers, Product Type & Application
- 3.7 Global Mesalazine API Manufacturers Established Date
- 3.8 Global Mesalazine API Market CR5 and HHI
- 3.9 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 YC Biotech (Jiangsu)
- 4.1.1 YC Biotech (Jiangsu) Mesalazine API Company Information
- 4.1.2 YC Biotech (Jiangsu) Mesalazine API Business Overview
- 4.1.3 YC Biotech (Jiangsu) Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.1.4 YC Biotech (Jiangsu) Product Portfolio
- 4.1.5 YC Biotech (Jiangsu) Recent Developments
- 4.2 Lianyungang Fengheng Biopharm
- 4.2.1 Lianyungang Fengheng Biopharm Mesalazine API Company Information
- 4.2.2 Lianyungang Fengheng Biopharm Mesalazine API Business Overview
- 4.2.3 Lianyungang Fengheng Biopharm Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.2.4 Lianyungang Fengheng Biopharm Product Portfolio
- 4.2.5 Lianyungang Fengheng Biopharm Recent Developments
- 4.3 Hangzhou Brother
- 4.3.1 Hangzhou Brother Mesalazine API Company Information
- 4.3.2 Hangzhou Brother Mesalazine API Business Overview
- 4.3.3 Hangzhou Brother Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.3.4 Hangzhou Brother Product Portfolio
- 4.3.5 Hangzhou Brother Recent Developments
- 4.4 Syntese A/S
- 4.4.1 Syntese A/S Mesalazine API Company Information
- 4.4.2 Syntese A/S Mesalazine API Business Overview
- 4.4.3 Syntese A/S Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.4.4 Syntese A/S Product Portfolio
- 4.4.5 Syntese A/S Recent Developments
- 4.5 PharmaZell
- 4.5.1 PharmaZell Mesalazine API Company Information
- 4.5.2 PharmaZell Mesalazine API Business Overview
- 4.5.3 PharmaZell Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.5.4 PharmaZell Product Portfolio
- 4.5.5 PharmaZell Recent Developments
- 4.6 Lasa Loboratory
- 4.6.1 Lasa Loboratory Mesalazine API Company Information
- 4.6.2 Lasa Loboratory Mesalazine API Business Overview
- 4.6.3 Lasa Loboratory Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.6.4 Lasa Loboratory Product Portfolio
- 4.6.5 Lasa Loboratory Recent Developments
- 4.7 Ishita Active Pharma Ingredients
- 4.7.1 Ishita Active Pharma Ingredients Mesalazine API Company Information
- 4.7.2 Ishita Active Pharma Ingredients Mesalazine API Business Overview
- 4.7.3 Ishita Active Pharma Ingredients Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.7.4 Ishita Active Pharma Ingredients Product Portfolio
- 4.7.5 Ishita Active Pharma Ingredients Recent Developments
- 4.8 Ipca Laboratories
- 4.8.1 Ipca Laboratories Mesalazine API Company Information
- 4.8.2 Ipca Laboratories Mesalazine API Business Overview
- 4.8.3 Ipca Laboratories Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.8.4 Ipca Laboratories Product Portfolio
- 4.8.5 Ipca Laboratories Recent Developments
- 4.9 Erregierre SpA
- 4.9.1 Erregierre SpA Mesalazine API Company Information
- 4.9.2 Erregierre SpA Mesalazine API Business Overview
- 4.9.3 Erregierre SpA Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.9.4 Erregierre SpA Product Portfolio
- 4.9.5 Erregierre SpA Recent Developments
- 4.10 Divis Laboratories
- 4.10.1 Divis Laboratories Mesalazine API Company Information
- 4.10.2 Divis Laboratories Mesalazine API Business Overview
- 4.10.3 Divis Laboratories Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.10.4 Divis Laboratories Product Portfolio
- 4.10.5 Divis Laboratories Recent Developments
- 4.11 CTX Lifescience
- 4.11.1 CTX Lifescience Mesalazine API Company Information
- 4.11.2 CTX Lifescience Mesalazine API Business Overview
- 4.11.3 CTX Lifescience Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.11.4 CTX Lifescience Product Portfolio
- 4.11.5 CTX Lifescience Recent Developments
- 4.12 Corden Pharma Bergamo
- 4.12.1 Corden Pharma Bergamo Mesalazine API Company Information
- 4.12.2 Corden Pharma Bergamo Mesalazine API Business Overview
- 4.12.3 Corden Pharma Bergamo Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.12.4 Corden Pharma Bergamo Product Portfolio
- 4.12.5 Corden Pharma Bergamo Recent Developments
- 4.13 Chemi SpA
- 4.13.1 Chemi SpA Mesalazine API Company Information
- 4.13.2 Chemi SpA Mesalazine API Business Overview
- 4.13.3 Chemi SpA Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.13.4 Chemi SpA Product Portfolio
- 4.13.5 Chemi SpA Recent Developments
- 4.14 Cambrex Corporation
- 4.14.1 Cambrex Corporation Mesalazine API Company Information
- 4.14.2 Cambrex Corporation Mesalazine API Business Overview
- 4.14.3 Cambrex Corporation Mesalazine API Production Capacity, Value and Gross Margin (2021-2026)
- 4.14.4 Cambrex Corporation Product Portfolio
- 4.14.5 Cambrex Corporation Recent Developments
5 Global Mesalazine API Production by Region
- 5.1 Global Mesalazine API Production Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mesalazine API Production by Region: 2021-2032
- 5.2.1 Global Mesalazine API Production by Region: 2021-2026
- 5.2.2 Global Mesalazine API Production Forecast by Region (2027-2032)
- 5.3 Global Mesalazine API Production Value Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 5.4 Global Mesalazine API Production Value by Region: 2021-2032
- 5.4.1 Global Mesalazine API Production Value by Region: 2021-2026
- 5.4.2 Global Mesalazine API Production Value Forecast by Region (2027-2032)
- 5.5 Global Mesalazine API Market Price Analysis by Region (2021-2026)
- 5.6 Global Mesalazine API Production and Value, YOY Growth
- 5.6.1 North America Mesalazine API Production Value Estimates and Forecasts (2021-2032)
- 5.6.2 Europe Mesalazine API Production Value Estimates and Forecasts (2021-2032)
- 5.6.3 China Mesalazine API Production Value Estimates and Forecasts (2021-2032)
- 5.6.4 Japan Mesalazine API Production Value Estimates and Forecasts (2021-2032)
6 Global Mesalazine API Consumption by Region
- 6.1 Global Mesalazine API Consumption Estimates and Forecasts by Region: 2021 VS 2025 VS 2032
- 6.2 Global Mesalazine API Consumption by Region (2021-2032)
- 6.2.1 Global Mesalazine API Consumption by Region: 2021-2026
- 6.2.2 Global Mesalazine API Forecasted Consumption by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Mesalazine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Mesalazine API Consumption by Country (2021-2032)
- 6.3.3 United States
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Mesalazine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Mesalazine API Consumption by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Russia
- 6.4.8 Spain
- 6.4.9 Netherlands
- 6.4.10 Switzerland
- 6.4.11 Sweden
- 6.4.12 Poland
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Mesalazine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Mesalazine API Consumption by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 India
- 6.5.7 Australia
- 6.5.8 Taiwan
- 6.5.9 Southeast Asia
- 6.6 South America, Middle East & Africa
- 6.6.1 South America, Middle East & Africa Mesalazine API Consumption Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East & Africa Mesalazine API Consumption by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 Argentina
- 6.6.5 Chile
- 6.6.6 Turkey
- 6.6.7 GCC Countries
7 Segment by Type
- 7.1 Global Mesalazine API Production by Type (2021-2032)
- 7.1.1 Global Mesalazine API Production by Type (2021-2032) & (t)
- 7.1.2 Global Mesalazine API Production Market Share by Type (2021-2032)
- 7.2 Global Mesalazine API Production Value by Type (2021-2032)
- 7.2.1 Global Mesalazine API Production Value by Type (2021-2032) & (US$ Million)
- 7.2.2 Global Mesalazine API Production Value Market Share by Type (2021-2032)
- 7.3 Global Mesalazine API Price by Type (2021-2032)
8 Segment by Application
- 8.1 Global Mesalazine API Production by Application (2021-2032)
- 8.1.1 Global Mesalazine API Production by Application (2021-2032) & (t)
- 8.1.2 Global Mesalazine API Production Market Share by Application (2021-2032)
- 8.2 Global Mesalazine API Production Value by Application (2021-2032)
- 8.2.1 Global Mesalazine API Production Value by Application (2021-2032) & (US$ Million)
- 8.2.2 Global Mesalazine API Production Value Market Share by Application (2021-2032)
- 8.3 Global Mesalazine API Price by Application (2021-2032)
9 Value Chain and Sales Channels Analysis of the Market
- 9.1 Mesalazine API Value Chain Analysis
- 9.1.1 Mesalazine API Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Mesalazine API Production Mode & Process
- 9.2 Mesalazine API Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Mesalazine API Distributors
- 9.2.3 Mesalazine API Customers
10 Global Mesalazine API Analyzing Market Dynamics
- 10.1 Mesalazine API Industry Trends
- 10.2 Mesalazine API Industry Drivers
- 10.3 Mesalazine API Industry Opportunities and Challenges
- 10.4 Mesalazine API Industry Restraints
11 Report Conclusion
12 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst